tailieunhanh - High incidence and early onset of nivolumab-induced pneumonitis: Four case reports and literature review

Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (irAEs), including pneumonitis. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN